The announcement came a few days ago: BioNTech and Pfizer, partner companies in the production of COVID-19 vaccines, will begin in the second half of the year, human tests of a new generation of drugs that protect against a wide variety coronavirus, as reported by Reuters. Their experimental work of the two pharmaceutical companies goes beyond the current approach and includes both vaccines that aim at potentiating T lymphocytesprimarily designed to protect against serious disease if the virus becomes more dangerous, either pan-coronavirus vaccineswhich protect against the large coronavirus family and its mutations.
The objective of the research being carried out in the two companies is to provide lasting protection of the variants. But that’s not all: the two partners, producers of the most widely used COVID-19 vaccine in the Western world, are currently discussing with regulators about a updated and improved version of their vaccinebetter able to protect from the Omicron variant and its sub-lineages.
However, the persistent mutation of the virus into new variants that more easily evade vaccine protection, in addition to reducing human immune memory, has also generated the urgency in research laboratories, governments and health agencies to seek protection tools. more reliable.
Precisely in this regard, in order to offer a further boost to its research activity on infectious diseases, BioNTech also stated that work on precision antibiotics that kill superbugs that have become resistant to currently available anti-infectives.
In fact, drug-resistant infections are on the rise, caused by the overuse of antibiotics. And the estimate relating to the number of people who die each year from antibiotic-resistant infections between the United States and the European Union would amount – according to public health experts – to almost 70,000 subjects.
Other stories of Vanity Fair that may interest you
Omicron 4 and 5, what the variants that infect even those who had remained “immune” mean for the pandemic
Omicron 5, with which symptoms the variant that will soon predominate in Italy manifests itself
Flu, hepatitis, bronchiolitis … The reappearance of the other viruses in unexpected ways, after two years of Covid
Source: Vanity Fair
